Table V.1: States That Reported Participating in FDA-Sponsored Activities Related to Drug Compounding, and How These States Rated the Helpfulness of Each Activity
Food and Drug Administration (FDA) sponsored activity Number of states that reported participating in activity (%) How states that reported participating in FDA-sponsored activities rated the helpfulness of each activity
  Yes No Don't know No response Very
helpful
Moderately
helpful
Slightly
helpful
Not at all
helpful
Donít know No response
FDA's March 2014 Intergovernmental Working Meeting on Pharmacy Compounding 41 (82) 2 (4) 4 (8) 3 (6) 15 18 4 0 2 2
FDA's March 2015 Intergovernmental Working Meeting on Pharmacy Compounding 37 (74) 7 (14) 4 (8) 2 (4) 11 17 5 0 3 1
FDA's November 2015 Intergovernmental Working Meeting on Pharmacy Compounding 35 (70) 11 (22) 1 (2) 3 (6) 13 12 5 1 2 2
FDA's Pharmacy Compounding Advisory Committee meeting, February 2015a 8 (16) 31 (62) 9 (18) 2 (4) 3 3 2 0 0 0
FDA's Pharmacy Compounding Advisory Committee meeting, June 2015a 7 (14) 34 (68) 5 (10) 4 (8) 2 3 2 0 0 0

Source: GAO survey of state pharmacy regulatory bodies, survey question 27. | GAO-17-363SP
Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.
aThe Drug Quality and Security Act, enacted in November 2013, required FDA to convene and consult with a Pharmacy Compounding Advisory Committee before issuing certain regulations.